Events & Ideas
September 21-24, 2022 | Haarlem, Netherlands Judy Ashworth will be attending and participating in a panel discussion. Novel Compounds or Existing Molecules Panelists: David Nichols, Michelle Baker-Jones, Paul Stamets, Judy Ashworth Moderator: Matthew Baggott VIEW CONFERENCE WEBSITE
June 22-25, 2022 | Aspen, CO Joe Gitchell will be attending and is happy to talk to/meet up with other attendees. VIEW CONFERENCE WEBSITE
June 11-15, 2022 | MINNEAPOLIS, MN
Jack Henningfield, August Buchhalter, and Ryan Lanier will be attending CPDD.
MAY 23–24, 2022 | WASHINGTON, DC
Following a presentation of the results from a 2021 survey of key stakeholders which elicited expert opinions on best practices and metrics to assess the safety of psychedelic drugs within the context of a REMS, as well as the most effective structure for such programs (e.g., individual vs. shared REMS programs), panelists in this session will discuss the most relevant aspects for designing appropriate REMS programs for this new class of medicines.
NOVEMBER 1–2, 2021 | WASHINGTON, DC The Potential Role for Psychedelic Drugs in the Treatment of Chronic Pain Psychedelic drugs are currently being evaluated for their efficacy in treating several neuropsychiatric conditions and may have a potential role as treatments for chronic pain. This panel session will explore the potential role that psychedelic drugs… Read More
SEPTEMBER 29–30, 2021 | VIRTUAL EVENT Judy Ashworth, MD, Vice President, Rx Strategic Services and Chief Medical Officer, Pinney Associates Clinical & Regulatory Challenges in Developing Psychedelics as Therapeutics Designing clinical trials that meet regulatory requirements without inadvertently stifling market access Managing the impact of CSA Schedule 1 status during development Building an optimal… Read More
Jack Henningfield, PhD, Vice President, Research, Health Policy, and Abuse Liability, Pinney Associates Presented as part of the NIH Psilocybin Speaker Series, April 22-June 10, 2021 VISIT THE SPEAKER SERIES WEBSITE
Marion Coe, PhD, Director, Clinical Development and Postmarketing Surveillance, Pinney Associates Presented as part of the session Hot Topics in Psychedelic Drug Development: From Successful Clinical Trials to Maximizing Benefits in the Post-approval World, May 5, 2021 VISIT THE CONFERENCE WEBSITE